Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 4,367 Shares of Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 4,367 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $6.54, for a total value of $28,560.18. Following the sale, the insider directly owned 383,201 shares in the company, valued at $2,506,134.54. This trade represents a 1.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The stock was sold at an average price of $6.45, for a total value of $36,003.90.
• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total value of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total value of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total value of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The shares were sold at an average price of $6.31, for a total transaction of $44,359.30.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total transaction of $68,664.20.
• On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The shares were sold at an average price of $6.79, for a total transaction of $51,624.37.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The shares were sold at an average price of $6.81, for a total transaction of $74,276.67.
• On Wednesday, December 10th, Chidozie Ugwumba sold 9,921 shares of Clene stock. The stock was sold at an average price of $6.42, for a total value of $63,692.82.
• On Tuesday, December 9th, Chidozie Ugwumba sold 15,031 shares of Clene stock. The shares were sold at an average price of $5.95, for a total value of $89,434.45.

Clene Price Performance

Clene stock traded down $0.18 during mid-day trading on Tuesday, hitting $6.26. 68,658 shares of the company were exchanged, compared to its average volume of 107,521. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50. The company has a market capitalization of $64.67 million, a P/E ratio of -1.85 and a beta of 0.79. The business’s 50 day simple moving average is $8.48 and its two-hundred day simple moving average is $6.26.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Equities research analysts predict that Clene Inc. will post -5.19 earnings per share for the current year.

Institutional Investors Weigh In On Clene

Institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp acquired a new position in Clene during the third quarter worth approximately $29,000. Jane Street Group LLC purchased a new stake in shares of Clene during the 2nd quarter valued at $47,000. Lunt Capital Management Inc. raised its position in shares of Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after buying an additional 21,217 shares during the period. Finally, Scoggin Management LP boosted its holdings in Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after acquiring an additional 42,750 shares during the last quarter. 23.28% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on CLNN shares. UBS Group reissued a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Benchmark reaffirmed a “buy” rating on shares of Clene in a research note on Thursday, December 4th. D. Boral Capital reiterated a “buy” rating and issued a $23.00 price target on shares of Clene in a report on Wednesday, December 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research note on Tuesday, October 14th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).